Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322673 · ClinicalTrials.gov registry record · Phase 2
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00322673: Clinical Trial Phase 2 study, sponsored by Symphony Evolution.
NCT00322673 is a Phase 2 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322673, a Phase 2 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c-Kit and FLT3 are receptors commonly expressed on AML blasts.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Why NCT00322673 stopped before completion
NCT00322673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00322673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322673 about?
NCT00322673 is a clinical study titled "Study of XL999 in Patients With Acute Myeloid Leukemia (AML)". This clinical study is being conducted at multiple sites to determine the activity, safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML. XL999 is a small molecule inhibitor against Flk1/kinase insert domain receptor (KDR), PDGFR, c-Kit, FLT3 and SRC. c...
What is the current status of trial NCT00322673?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-05. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00322673?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00322673?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00322673's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia